- Home
- ADAM vs FBRX Comparison
ADAM vs FBRX Comparison
Compare ADAM & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAM | FBRX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.7M | 899.4M |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ADAM | FBRX |
|---|---|---|
| Price | $10.14 | $76.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $9.17 | ★ $67.00 |
| AVG Volume (30 Days) | 885.3K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.87% | N/A |
| EPS Growth | ★ 196.49 | 61.30 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.08 | N/A |
| P/E Ratio | $11.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.45 | $10.18 |
| 52 Week High | $10.36 | $77.20 |
Technical Indicators
Market Signals| Indicator | ADAM | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 84.48 |
| Support Level | $8.61 | $26.51 |
| Resistance Level | N/A | $77.20 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | 0.13 | -1.16 |
| Stochastic Oscillator | 88.84 | 57.93 |
Price Performance
Historical ComparisonAbout ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.